Viking Therapeutics (VKTX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.87 (+1.74%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Viking Therapeutics (VKTX)
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Key Insights

Critical company metrics and information
  • Share Price

    $50.80
  • Market Cap

    $5.66 Billion
  • Total Outstanding Shares

    111.44 Million Shares
  • Total Employees

    34
  • Dividend

    No dividend
  • IPO Date

    April 29, 2015
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.vikingtherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-524.22 Million
Net Cash Flow From Operating Activities, Continuing$-74.25 Million
Net Cash Flow From Operating Activities$-74.25 Million
Net Cash Flow From Investing Activities, Continuing$-524.22 Million
Net Cash Flow$13.19 Million
Net Cash Flow, Continuing$13.19 Million
Net Cash Flow From Financing Activities$611.65 Million
Net Cash Flow From Financing Activities, Continuing$611.65 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Average Shares$219.70 Million
Diluted Earnings Per Share$0.93
Revenues$0.00
Income/Loss From Continuing Operations After Tax$-99.15 Million
Income/Loss From Continuing Operations Before Tax$-99.15 Million
Operating Income/Loss$-133.97 Million
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss$-99.15 Million
Net Income/Loss Available To Common Stockholders, Basic$-99.15 Million
Other Operating Expenses$42.81 Million
Operating Expenses$133.97 Million
Research and Development$91.16 Million
Basic Average Shares$219.70 Million
Net Income/Loss Attributable To Parent$-99.15 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Basic Earnings Per Share$0.93

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$936.65 Million
Liabilities And Equity$937.89 Million
Equity$911.45 Million
Noncurrent Liabilities$755000.00
Equity Attributable To Parent$911.45 Million
Equity Attributable To Noncontrolling Interest$0.00
Accounts Payable$254000.00
Other Current Liabilities$25.43 Million
Liabilities$26.44 Million
Assets$937.89 Million
Noncurrent Assets$1.24 Million
Current Liabilities$25.68 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Related Companies

View additional S&P 500 companies similar to Viking Therapeutics (VKTX)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.